-

Thermo Fisher Scientific Launches Scalable Diomni Enterprise Software for Molecular Diagnostics Labs and Test Developers

Time to qPCR-based diagnostic results reduced by over two hours and improved lab collaboration with automated quality control and interpretation

CARLSBAD, Calif.--(BUSINESS WIRE)--To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results. By connecting workflow steps within one interface, Diomni Enterprise can increase a lab’s ability to dynamically respond to today’s rapidly changing testing environment. The solution can be used by a variety of labs performing routine quantitative polymerase chain reaction (qPCR) diagnostic tests and by developers to increase the speed of innovation for emerging testing solutions.

Molecular diagnostics clinical labs and kit manufacturers often suffer from antiquated systems that can be hard to scale for increased throughput or expanding test menu. Further, manual and inefficient steps may make it difficult to track samples and maintain compliance, which is critical for a molecular diagnostics laboratory. For assay developers, transitions between development stages and a lack of process standardization can slow time-to-market and jeopardize regulatory compliance.

Addressing these challenges, Diomni Enterprise seamlessly connects the individual steps of the workflow in one unified platform to improve productivity of qPCR workflows. Diomni Enterprise empowers labs to operate at their highest potential by automating the interface with existing laboratory information systems (LIS) for enhanced efficiency and traceability.

“During the pandemic, we worked to quickly launch a digital solution that would allow clinical labs to continue operations, taking into account the dramatic changes in the PCR testing landscape,” said Fernando Beils, vice president, general manager of qPCR instruments, Thermo Fisher Scientific. “What followed was the earliest stages of the Diomni solution, delivering a digital platform that supports testing workflows with the flexibility required to accommodate rapidly evolving needs. We have continued to build on this platform and are excited to deliver a more robust and scalable tool for labs and assay developers across testing environments.”

Uniting labs with instruments, assays, and LIS on one system can increase traceability to track samples and reagents throughout the sample journey and allows multiple individual users to access assay templates and results at the same time. Diomni Enterprise supports a variety of different testing workflows including compatibility with research-use only and in vitro diagnostic assays and instruments.

“The new Diomni Software makes it easy to work collaboratively, and we can set up runs, manage past runs and documentation, and interpret fluorescent curves remotely and efficiently without the need to install special software," said Dr. Gustav Quade, laboratory medicine and technical development clinical pathologist at Quade Laboratory in Germany.

The Diomni Enterprise software will be available for live demonstrations in Thermo Fisher Scientific’s booth #2118 at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo from July 23-27, 2023 in Anaheim, Calif. To learn more about the Diomni Enterprise Software, please visit thermofisher.com/diomni.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:

Catie Shaw
Phone: 442-303-2104
E-mail: caitlin.campbell@thermofisher.com

Jessika Parry
Phone: 419-266-4016
Email: jparry@greenoughagency.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:

Catie Shaw
Phone: 442-303-2104
E-mail: caitlin.campbell@thermofisher.com

Jessika Parry
Phone: 419-266-4016
Email: jparry@greenoughagency.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom